Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin

Biochemical Engineering Journal

Volumn 68, Issue , 2012, Pages 61-69

  Bulmer, Cody ^a   Margaritis, Argyrios ^a   Xenocostas, Anargyros ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Chitosan; Controlled release; Encapsulation; Erythropoietin; Ionotropic gelation; Nanoparticles; Response surface modeling

Indexed keywords

ANIMAL MODEL; CHITOSAN CONCENTRATION; CHITOSAN NANOPARTICLES; CONTROLLED RELEASE; ERYTHROPOIETIN (EPO); HUMAN ERYTHROPOIETIN; IONOTROPIC GELATION; MASS RATIO; NANOPARTICLE SURFACE CHARGE; PARTICLE POLYDISPERSITY; RESPONSE SURFACE MODELING; SOLUTION PH; TRIPOLYPHOSPHATES;

CHITOSAN; ENCAPSULATION; GELATION; SURFACE PROPERTIES; ZETA POTENTIAL;

NANOPARTICLES;

CHITOSAN; NANOPARTICLE; RECOMBINANT ERYTHROPOIETIN; TRIPOLYPHOSPHATE;

ARTICLE; CONTROLLED DRUG RELEASE; ENCAPSULATION; GELATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; SURFACE CHARGE; ZETA POTENTIAL;

ANIMALIA;

EID: 84864421204     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2012.07.007     Document Type: Article

References (39)

1. Kurita K. Chitin and Chitosan: functional biopolymers from marine crustaceans. Mar. Biotechnol. 2006, 8:203-226.
2. Shanji J., Jain V., Lodha S. Chitosan: a novel pharmaceutical excipient. Int. J. Pharm. Appl. Sci. 2010, 1:11-28.
3. Hirano S., Seino H., Akiyama Y., Nonaka I. Biocompatibility of chitosan by oral and intravenous administration. Polym. Eng. Sci. 1989, 59:897-901.
4. Dornish M., Hagen A., Hansson E., Pecheur C., Verdier F., Skaugrad O. Safety of protasan: ultrapure chitosan salts for biomedical and pharmaceutical use. Adv. Chitin Sci. 1997, 2:664-670.
5. Lehr C.M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 1992, 78:43-48.
6. He P., Davis S.S., Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. 1997, 166:75-88.
7. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm. 2004, 274:1-33.
8. Huang M., Khor E., Lim L.Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 2004, 21:344-353.
9. Bhaskara Rao S., Sharma C.P. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 1997, 34:21-28.
10. Chandy T., Sharma C.P. Chitosan beads and granules for oral sustained delivery of nifepine: in vitro studies. Biomaterials 1992, 13:949-952.
11. Fernandez-Urrusuno R., Calvo P., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 1999, 16:1576-1581.
12. Ma Z., Yeoh H.H., Lim L.Y. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J. Pharm. Sci. 2002, 91:1396-1404.
13. Upadrashta S.M., Katikaneni P.R., Nuessle N.O. Chitosan as a tablet binder. Drug Dev. Ind. Pharm. 1992, 18:1701-1708.
14. Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E. Structural characterization of human erythropoietin. J. Biol. Chem. 1986, 261:3116-3121.
15. Mocini M., Leone T., Tubaro M., Santini M., Penco M. Structural, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr. Med. Chem. 2007, 14:2278-2287.
16. Walsh G. Biopharmaceuticals - Biochemistry and Biotechnology 2003, John Wiley, USA. 2nd ed.
17. Wojchowski D. Eugene Goldwasser (1922-2010). Nature 2011, 470:40.
18. Broudy V.C., Tait J.F., Powell J.S. Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch. Biochem. Biophys. 1988, 265:329-336.
19. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., Badrawi S.M., Lai P.L., Goldwasser E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci U.S.A. 1985, 82:7580-7584.
20. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. Med. 1989, 321:158-163.
21. Pistel K.F., Bittner B., Koll H., Winter G., Kissel T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polymer composition on particle characteristics. J. Control. Release 1999, 59:309-325.
22. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br. J. Haematol. 2008, 141:14-31.
23. Boogaerts M. Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr. Med. Res. Opin. 2006, 22:15-22.
24. Burger D., Lei M., Geoghegan-Morphet N., Lu X., Xenocostas A., Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 2006, 72:51-59.
25. Kao R., Xenocostas A., Rui T., Yu P., Huang W., Rose J., Martin M.C. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit. Care 2007, 11:58.
26. Rui T., Fen Q., Lei M., Peng T., Zhang J., Xu M., Abel E.D., Xenocostas A., Kvietys R.P. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovas. Res. 2005, 65:719-727.
27. Vander M., Voors A.A., Lipsic E., Van Gilst H.W., Van Velduisen D.J. Erythropoietin in cardiovascular diseases. Eur. Heart J. 2004, 25:285-291.
28. Morlock M., Koll H., Winter G., Kissel T. Microencapsulation of rh-Erythropoietin, using biodegradable poly (d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm. 1997, 43:29-36.
29. Prestwich G.D., Marecak D.M., Marecek J.F., Vercruysse K.P., Ziebell M.R. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J. Control. Release 1998, 53:93-103.
30. Patil J.S., Kamalapur M.V., Marapur S.C., Kadam D.V. Ionotropic gelation and polyelectrolyte complexation: the novel techniques to design hydrogel particulate sustained, modulated drug delivery system: a review. Dig. J. Nanomater. Bios. 2010, 5:241-248.
31. Vinogradov S.V., Bronich T.K., Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 2002, 54:135-147.
32. Anderson M.J., Whitcomb P.J. RSM Simplified: Optimizing Processes Using Response Surface Methods for Design of Experiments 2005, CRC Press, New York.
33. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloid. Surface B 2005, 44:65-73.
34. Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 1997, 14:1568-1573.
35. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
36. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
37. Calvo P., Vila-Jato J.L., Alonso M.J. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Biomaterials 1997, 18:1305-1310.
38. Bokharaei M., Margaritis A., Xenocostas A., Freeman D.J. Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release. Curr. Drug Del. 2011, 8:164-171.
39. Gan Q., Wang T. Chitosan nanoparticle as protein delivery carrier - systematic examination of fabrication conditions for efficient loading and release. Colliod Surface B 2007, 59:24-34.